🚀 VC round data is live in beta, check it out!
Mainz Biomed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mainz Biomed and similar public comparables like Ludwig Enterprises, Diagonal Bio, 2cureX, Glycorex Transplantation and more.
Mainz Biomed Overview
About Mainz Biomed
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
Founded
2021
HQ
Employees
26
Website
Sectors
Financials (LTM)
EV
$8M
Mainz Biomed Financials
Mainz Biomed reported last 12-month revenue of $887K.
In the same LTM period, Mainz Biomed generated $555K in gross profit and had net loss of ($16M).
Revenue (LTM)
Mainz Biomed P&L
In the most recent fiscal year, Mainz Biomed reported revenue of $874K and EBITDA of ($15M).
Mainz Biomed expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $887K | XXX | $874K | XXX | XXX | XXX |
| Gross Profit | $555K | XXX | $390K | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($15M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1742%) | XXX | XXX | XXX |
| EBIT Margin | (1821%) | XXX | (1483%) | XXX | XXX | XXX |
| Net Profit | ($16M) | XXX | ($16M) | XXX | XXX | XXX |
| Net Margin | (1841%) | XXX | (1855%) | XXX | XXX | XXX |
| Net Debt | — | — | $334K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mainz Biomed Stock Performance
Mainz Biomed has current market cap of $6M, and enterprise value of $8M.
Market Cap Evolution
Mainz Biomed's stock price is $0.47.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8M | $6M | -3.4% | XXX | XXX | XXX | $-1.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMainz Biomed Valuation Multiples
Mainz Biomed trades at 8.5x EV/Revenue multiple, and (0.5x) EV/EBITDA.
EV / Revenue (LTM)
Mainz Biomed Financial Valuation Multiples
As of April 21, 2026, Mainz Biomed has market cap of $6M and EV of $8M.
Equity research analysts estimate Mainz Biomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mainz Biomed has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV (current) | $8M | XXX | $8M | XXX | XXX | XXX |
| EV/Revenue | 8.5x | XXX | 8.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/EBIT | (0.5x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 13.6x | XXX | 19.4x | XXX | XXX | XXX |
| P/E | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mainz Biomed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mainz Biomed Margins & Growth Rates
Mainz Biomed's revenue in the last 12 month grew by 3%.
Mainz Biomed's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.
Mainz Biomed Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1742%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (22%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 314% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 626% | XXX | 702% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 742% | XXX | 802% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1528% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mainz Biomed Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mainz Biomed | XXX | XXX | XXX | XXX | XXX | XXX |
| Ludwig Enterprises | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagonal Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| 2cureX | XXX | XXX | XXX | XXX | XXX | XXX |
| Glycorex Transplantation | XXX | XXX | XXX | XXX | XXX | XXX |
| Integragen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mainz Biomed M&A Activity
Mainz Biomed acquired XXX companies to date.
Last acquisition by Mainz Biomed was on XXXXXXXX, XXXXX. Mainz Biomed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mainz Biomed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMainz Biomed Investment Activity
Mainz Biomed invested in XXX companies to date.
Mainz Biomed made its latest investment on XXXXXXXX, XXXXX. Mainz Biomed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mainz Biomed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mainz Biomed
| When was Mainz Biomed founded? | Mainz Biomed was founded in 2021. |
| Where is Mainz Biomed headquartered? | Mainz Biomed is headquartered in Germany. |
| How many employees does Mainz Biomed have? | As of today, Mainz Biomed has over 26 employees. |
| Who is the CEO of Mainz Biomed? | Mainz Biomed's CEO is Guido Baechler. |
| Is Mainz Biomed publicly listed? | Yes, Mainz Biomed is a public company listed on Nasdaq. |
| What is the stock symbol of Mainz Biomed? | Mainz Biomed trades under QUCY ticker. |
| When did Mainz Biomed go public? | Mainz Biomed went public in 2021. |
| Who are competitors of Mainz Biomed? | Mainz Biomed main competitors are Ludwig Enterprises, Diagonal Bio, 2cureX, Glycorex Transplantation. |
| What is the current market cap of Mainz Biomed? | Mainz Biomed's current market cap is $6M. |
| What is the current revenue of Mainz Biomed? | Mainz Biomed's last 12 months revenue is $887K. |
| What is the current revenue growth of Mainz Biomed? | Mainz Biomed revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Mainz Biomed? | Current revenue multiple of Mainz Biomed is 8.5x. |
| Is Mainz Biomed profitable? | No, Mainz Biomed is not profitable. |
| What is the current net income of Mainz Biomed? | Mainz Biomed's last 12 months net income is ($16M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.